Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

387 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Safety of Bladder Preservation Therapy in Combination with Atezolizumab and Radiation Therapy (BPT-ART) for Invasive Bladder Cancer: Interim Analysis from a Multicenter, Open-label, Prospective Phase 2 Trial.
Kimura T, Ishikawa H, Nagumo Y, Sekino Y, Kageyama Y, Ushijima H, Kawai T, Yamashita H, Azuma H, Nihei K, Takemura M, Hashimoto K, Maruo K, Tsuzuki T, Nishiyama H; BPT-ART Investigators Group. Kimura T, et al. Among authors: maruo k. Int J Radiat Oncol Biol Phys. 2023 Nov 1;117(3):644-651. doi: 10.1016/j.ijrobp.2023.05.013. Epub 2023 May 15. Int J Radiat Oncol Biol Phys. 2023. PMID: 37196834 Free article. Clinical Trial.
An Analysis of Vertebral Body Growth after Proton Beam Therapy for Pediatric Cancer.
Baba K, Mizumoto M, Oshiro Y, Shimizu S, Nakamura M, Hiroshima Y, Iizumi T, Saito T, Numajiri H, Nakai K, Ishikawa H, Okumura T, Maruo K, Sakurai H. Baba K, et al. Among authors: maruo k. Cancers (Basel). 2021 Jan 19;13(2):349. doi: 10.3390/cancers13020349. Cancers (Basel). 2021. PMID: 33477867 Free PMC article.
Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) - A study protocol for an open-label, phase II, multicenter study.
Sekino Y, Ishikawa H, Kimura T, Kojima T, Maruo K, Azuma H, Yoshida K, Kageyama Y, Ushijima H, Tsuzuki T, Sakurai H, Nishiyama H. Sekino Y, et al. Among authors: maruo k. Contemp Clin Trials Commun. 2021 Jan 21;21:100724. doi: 10.1016/j.conctc.2021.100724. eCollection 2021 Mar. Contemp Clin Trials Commun. 2021. PMID: 33615035 Free PMC article.
Risk factor of pneumonitis on dose-volume relationship for chemoradiotherapy with durvalumab: Multi-institutional research in Japan.
Oshiro Y, Mizumoto M, Sekino Y, Maruo K, Ishida T, Sumiya T, Nakamura M, Ohkawa A, Takizawa D, Okumura T, Tamaki Y, Sakurai H. Oshiro Y, et al. Among authors: maruo k. Clin Transl Radiat Oncol. 2021 May 29;29:54-59. doi: 10.1016/j.ctro.2021.05.009. eCollection 2021 Jul. Clin Transl Radiat Oncol. 2021. PMID: 34151033 Free PMC article.
Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors.
Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, Negoro H, Mathis BJ, Maruo K, Miura K, Sakamoto N, Shinohara N, Yamashita S, Yonemori K, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Kawahara T, et al. Among authors: maruo k. Int J Urol. 2022 Jul;29(7):741-747. doi: 10.1111/iju.14885. Epub 2022 Apr 23. Int J Urol. 2022. PMID: 35462438 Free PMC article. Clinical Trial.
A Japanese registry study and systematic review of particle therapy for renal cell carcinoma.
Ishikawa H, Arimura T, Maruo K, Kawamura H, Toyama S, Ogino T, Okimoto T, Murakami M, Sato Y, Nishioka K, Araya M, Ohba H, Umehara K, Aoyama H, Obara W, Azuma H, Tsuji H, Sakurai H. Ishikawa H, et al. Among authors: maruo k. J Radiat Res. 2023 Jun 16;64(Supplement_1):i41-i48. doi: 10.1093/jrr/rrad010. J Radiat Res. 2023. PMID: 37045797 Free PMC article.
387 results